Physician profile
Victor Yu
NPI 1235205477
$13,439.48
in general payments reported to CMS, 2019-2025
43 companies · $2,646 in 2025
The $2,646 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $827 · 2021: $1,285 · 2022: $2,208 · 2023: $2,326 · 2024: $2,551 · 2025: $2,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,508 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,508.43 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,303.36 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $1,295.86 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,287.56 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $777.11 | 2019-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $709.67 | 2020-2023 | |
| Gilead Sciences, INC. | $607.52 | 2019-2025 | |
| Genzyme Corporation | $581.72 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $451.67 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $445.32 | 2022-2025 | Dupixent |
| Pfizer INC. | $316.11 | 2019-2025 | |
| Lilly USA, LLC | $300.50 | 2023-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $239.46 | 2020-2022 | |
| Celltrion USA INC. | $171.45 | 2024-2025 | Vegzelma, Zymfentra |
| Celgene Corporation | $154.00 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $148.91 | 2023-2025 | Sucraid, Sucraid |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.